Abstract: The present invention relates to a method of enhancing cognition without producing convulsions which method comprises administering to a subject in need thereof a cognition enhancing amount of a compound which is a GABAa selective alpha5 receptor inverse agonist.

Abstract: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.

Abstract: An automated packaging line has capability of filling large and small orders, of one or more bottles, each bottle filled with a respective one of a plurality of different pharmaceutical tablets, in a single run. Structure is provided for filling orders for an individual consumer, for a pharmacist, and for a wholesaler, simultaneously, using differently sized bottles, and providing customized labels for each bottle. A flexible filler station simultaneously fills plural bottles with respective tablets. An intelligent data carrying puck carries each bottle, including therein information describing, among others, the bottle, the customer, the order, the pharmaceutical, the bottle size and label information. Puck handling stations (PHS) are dispersed throughout the line, to verify a number of operations implemented on the line and to reject a puck at the earliest opportunity, while permitting subsequent rejection by a subsequent PHS.

Abstract: A novel process is provided for the preparation of 3-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-propylamine which is useful in the synthesis of &agr;v integrin receptor antagonists. Also provided are useful intermediates obtained from the process.

Abstract: The present invention relates to lithium fluoroalkylphosphates, a process for preparing them and their use as electrolyte salts in batteries, capacitors, supercapacitors and electrolytic cells.

Abstract: Combinations of a prostaglandin or an opthalmologically acceptable salt thereof and a topical carbonic anhydrase inhibitor or an opthalmologically acceptable salt thereof are particularly useful in the treatment of ocular hypertension and glaucoma. The combinations are characterized by an improved effect and reduced side-effects.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I 1

Abstract: The present invention relates to improved bone sealants for staunching local haemorrhages on bones, which are characterized in that the bone sealant consists of a polyester oligomer synthesized from polyol, lactide and glycolide, and water-soulble polymers.

Abstract: Disclosed is a method for enzymatic splitting of rutinosides, whereby rhamnose and/or corresponding glucopyranosides is/are obtained The inventive method is carried out in the presence of a solvent mixture made up of water and one or several organic solvents.

Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.

Abstract: Ortho-substituted arylmetal compounds are prepared by deprotonation of aromatics which have a hydrogen atom in the ortho position relative to at least one halogen atom, one trifluoromethoxy group, one dialkylamino group, one nitrile group, one alkoxy group or one dialkylamido group. The arylmetal compounds can then be reacted with electrophilic reagents. Deprotonation of the aromatics is carried out using alkyl- or arylmetal compounds or metal hydrides in the presence of a catalytic amount of a secondary metal amide.

Abstract: The present invention is directed to certain spiropiperidines of the general structural formula: wherein R1, R2, R3, R3a, R3b, R4 and R5 are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.

Abstract: The invention relates to a process of preparing a multilayer cholesteric film comprising two or more layers of polymerized cholesteric liquid crystal (CLC) material with planar orientation, with the cholesteric helix axis oriented substantially perpendicular to the plane of the layer, wherein that the cholesteric helical pitch of adjacent layers is varied by controlled migration of a non-polymerized chiral material between the layers, to a multilayer cholesteric film obtainable by such a process, and to the use of the process and a multilayer cholesteric film thereby prepared in optical elements such as polarizers, compensators, alignment layers, color filters or holographic elements, in cosmetics and liquid crystal pigments, for decorative and security applications.

Abstract: The invention relates to a process as described in claim of preparing a reflective film comprising a layer of a polymerized mesogenic material with helically twisted structure, wherein the helix axis is perpendicular to the film plane, and containing regions with varying helical pitch, to a reflective film obtainable by such a process, to the use of such a reflective film as reflective broadband or notch polarizer or as a multicoloured film or image in liquid crystal displays, as colour filter, in effect pigments, for decorative or security applications, and to a liquid crystal display comprising a liquid crystal cell and a reflective polarizer as described in the foregoing and the following, and optionally further comprising one or more compensaters or polarizers.

Abstract: 2-lithio-5-halopyridine is formed as a predominant component of a reaction mixture by reacting BuLi with 2,5-dihalopyridine in a non-coordinating solvent.

Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

Abstract: The present invention generally relates to a catalyst system. The catalyst system can include a metal dioxide of titanium dioxide or hafnium dioxide, as well as a cocatalys of the general formula (IV) or (V): M′(s+)(O-isopropyl)s  (IV) R3SiX  (V) where: M′ is Al, Ca, Na, K, Si or Mg, s is an integer from 1 to 4 and is the oxidation state of the metal, R is alkyl having 1 to 10 C atoms or aryl having 6 to 20 C atoms, and X is F, Cl, Br, CN; or the general formulae (CH3)2Clsi(CH2)2SiCl(CH3)2 (CH3)2ClSi(CH2)3CN [(CH3)3Si]2O [(CH3)3Si]2NH or [(CH3)3Si]2.

Abstract: Liquid-crystalline media comprising one or more compounds of each of the formulae I and II in which R1, R21, R22, L, Y21, Y22, n and m are as defined herein, and liquid-crystal displays containing same, have low frequency dependence of the dielectric properties in particular at low temperatures.

Abstract: The present invention relates to rare earth metal sulfide or oxysulfide pigments and yttrium sulfide or oxysulfide pigments based on platelet-shaped substrates.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.